<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01806961</url>
  </required_header>
  <id_info>
    <org_study_id>SP848-AKEx-1209</org_study_id>
    <nct_id>NCT01806961</nct_id>
  </id_info>
  <brief_title>Observational Trial Tolerability and Efficacy of Resiquimod Gel in Patients Treated for Actinic Keratosis.</brief_title>
  <official_title>Observational (Non-interventional), Follow-up Trial Assessing Long-term Local Tolerability and Efficacy (Recurrence Rate) of Resiquimod Gel in Patients Treated for Actinic Keratosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spirig Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spirig Pharma Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the recurrence rate of actinic keratosis (AK) lesions in patients with complete
      clinical clearance at the end of the previous trial SP848-AK-1101 at 6 and 12 months of
      follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy Evaluation:

      • Primarily based on clinical inspection of the former 25 cm2 treatment area and count of the
      AK-lesions.

      Safety Evaluation:

        -  Evaluation of adverse events (AEs) and serious adverse events (SAEs)

        -  Evaluation of newly occurred dermal adverse events (AEs) and serious adverse events
           (SAEs) in the previous treatment area at 6 months and 12 months of follow-up (local
           tolerability).

        -  Follow-up of unresolved adverse and serious adverse events that occurred in the previous
           trial SP848-AK-1101.

        -  Follow-up of unresolved abnormal laboratory values that occurred in the previous trial
           SP848-AK-1101.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    sponsor decision
  </why_stopped>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the Recurrence Rate of AK-lesions</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <description>Number of patients with persistent complete clearance at 6 and 12 months follow-up. Recurrence rate is to be determined at the same treatment area where the investigational medicinal products were administered in the previous trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Follow-up of AK-lesions (Existing Lesions, New Lesions, Changes)</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <description>clinical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Newly Occurred Dermal Adverse and Serious Adverse Events on the Previous Treatment Area</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <description>recording of adverse events</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">16</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>clearance at end of trial SP848-AK-1101</arm_group_label>
    <description>no trial medication during this follow-up trial</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with complete clinical clearance (i.e. no previously existing AK-lesion present) at
        the end of the trial SP848-AK-1101 or Non- Responder who withdrew from the trial
        prematurely.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent.

          -  Participation in the previous clinical trial SP848-AK-1101.

          -  Patient with complete clinical clearance (i.e. no previously existing AK-lesion
             present) at the end of the trial SP848-AK-1101 or Non-Responder who withdrew from the
             trial prematurely.

        Exclusion Criteria:

          -  Evidence of unstable or uncontrolled clinically significant medical conditions as
             determined by the investigator (e.g., cardiovascular, immunological, hematologic,
             hepatic, neurologic, renal, endocrine, collagen-vascular, infectious, gastrointestinal
             abnormalities or diseases).

          -  Evidence of systemic cancer.

          -  Dermatological disease or condition in the former treatment or surrounding area that
             might impair trial assessments (e.g., rosacea, atopic dermatitis, eczema) as assessed
             by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars E French, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic of Dermatology, Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hauttumorcentrum Charité (HTCC)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Zentrum Bonn - Friedensplatz</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautzentrum</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KLINIKUM VEST GmbH Knappschaftskrankenhaus</name>
      <address>
        <city>Recklinghausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St.Gallen</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2013</study_first_submitted>
  <study_first_submitted_qc>March 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2013</study_first_posted>
  <results_first_submitted>December 14, 2015</results_first_submitted>
  <results_first_submitted_qc>December 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 20, 2016</results_first_posted>
  <last_update_submitted>June 21, 2016</last_update_submitted>
  <last_update_submitted_qc>June 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SP848-AK-1101</title>
          <description>Patients from SP848-AK-1101 trial</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clearance at End of Trial SP848-AK-1101</title>
          <description>no trial medication during this follow-up trial</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" lower_limit="53" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Determine the Recurrence Rate of AK-lesions</title>
        <description>Number of patients with persistent complete clearance at 6 and 12 months follow-up. Recurrence rate is to be determined at the same treatment area where the investigational medicinal products were administered in the previous trial.</description>
        <time_frame>at 6 and 12 months</time_frame>
        <population>No subject was analysed due to premature study termination (sponsor's decision) therefore no data was available for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Patients from SP848-AK-1101 trial</description>
          </group>
        </group_list>
        <measure>
          <title>Determine the Recurrence Rate of AK-lesions</title>
          <description>Number of patients with persistent complete clearance at 6 and 12 months follow-up. Recurrence rate is to be determined at the same treatment area where the investigational medicinal products were administered in the previous trial.</description>
          <population>No subject was analysed due to premature study termination (sponsor's decision) therefore no data was available for analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Follow-up of AK-lesions (Existing Lesions, New Lesions, Changes)</title>
        <description>clinical examination</description>
        <time_frame>at 6 and 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Newly Occurred Dermal Adverse and Serious Adverse Events on the Previous Treatment Area</title>
        <description>recording of adverse events</description>
        <time_frame>at 6 and 12 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>Patients from SP848-AK-1101 trial</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinome lower back</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>oesophageal acid reflux</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>unspecific inflammation crus helicis left arm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>common cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypercholesterolemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>wart</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>carotid stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is an agreement between the PI and the Sponsor that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Investigator is granted a right to publish and present Trial Results together with other investigators of Trial and to be referred to in publications containing such results. However, PI shall not publish or present Results unless Investigator has submitted to Spirig a draft of the intented publication or presentation for review and approval.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No efficacy analysis was carried out since due to premature study termination (upon Sponsor's decision) no data was available for analysis</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Francine Santoro</name_or_title>
      <organization>Sipirig AG</organization>
      <phone>+41 62 387 87 87 ext 87 20</phone>
      <email>francine.santoro@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

